<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Submission to the Commons Select Committee  November 6th 2013</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by Antibiotic Discovery-UK </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">(AMR</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">0017</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Antibiotic Discovery-UK is a</span><span style="font-family:'Times New Roman'; font-size:11pt"> not-for-profit </span><span style="font-family:'Times New Roman'; font-size:11pt">network of leading academic researchers and universities together with SMEs all of whom have a common goal of revitalising of antibiotic discovery research in the UK.</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Terms of Reference</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We address the following: </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">a)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified? </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">b)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">What global coordination and action is required to fight antimicrobial resistance and is the UK contributing e</span><span style="font-family:'Times New Roman'; font-size:11pt">nough towards cros</span><span style="font-family:'Times New Roman'; font-size:11pt">s-border initiatives?</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">c)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Summary  </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We do not believe that there is sufficient research and investment into new antibiotics to ensure continued protection against infection.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We propose a</span><span style="font-family:'Times New Roman'; font-size:11pt"> Cross Research Council group (MRC, BBSRC, EPSRC, NIHR) initiate a program of  fundamental and developmental research into  antibiotics for the prevention and treatment of bacterial infections.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">NHS England should commission NICE to compile a report on the Limited Population Antimicrobial Drug Pathway and antibiotic unit price relating to encouraging industry into the AMR field.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The UK government should discuss with the European Commission an Antibiotic Recovery Plan along the lines of the Marshall Plan or the Public Health Emergency Medical Countermeasures Enterprise.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The UK government encourages EU to expand the IMI program focus on antibiotic discovery and development</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The UK government should encourage the formation of  a global network for antibiotic discovery and development. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We welcome and support the Government’s five year plan. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Its strengths are that it most importantly identifies the problems, and proposes seven key areas for future action. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We have described above some areas which we believe could add weight to the five year plan. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">                                                               </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">                                                                                                                                                                    </span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Evidence</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">a)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?   </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We propose that this could be rectified in the following ways: </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">i)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Research</span><span style="font-family:'Times New Roman'; font-size:11pt">: </span><span style="font-family:'Times New Roman'; font-size:11pt">We propose that in recognition that modern medicine cannot continue in its present form without effective antibiotics,  that a  Cross Research Council group,  consisting of the  Medical Research Council (MRC), the Biotechnology and Biological Sciences Research Council (BBSRC) and the Engineering and Physical Sciences Research Council(EPSRC) and the  National Institute for Health Research (NIHR) of the United Kingdom initiate a program of research with the aim of conducting fundamental and developmental research into  antibiotics for the prevention and treatment of bacterial infections. The Cross Research Council Antibiotic Research Program (CRCA) would add to existing investment by Research Councils and Charitable bodies. It would support innovation in the public sector and industry for the enhanced development of commercial antibiotics and diagnostics , which would be expected to lead to improvements in NHS care and preventative medicine. In addition it will provide new insights into bacterial infectious diseases. It will further enhance the UK’s international reputation, the home of Alexander Fleming, as a world leader in antibiotic research. Such an investment would provide a significant stimulus to the pharmaceutical sector in particular and the economy more generally.  </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The CRCA would link at least eight universities and centres across the UK and have strong links to industry.  The UK is home to a wide range of outstanding scientists with innovative approaches and skills which range from medical and biological to physical sciences who will combine their expertise to enable new discoveries in antibiotic research with a speed and scale not previously possible, even in industry. The concentration of funding in UK Antibiotic Research will provide a focus to enhance existing and emerging collaborations into strong nodes of activity with the pharmaceutical industry and this would attract inward investment into the UK economy. We propose that modelled on the Farr Institute (2013</span><span style="font-family:'Times New Roman'; font-size:11pt">),</span><span style="font-family:'Times New Roman'; font-size:11pt"> special funding  for capital and grant  support is provided by the British </span><span style="font-family:'Times New Roman'; font-size:11pt">Government for a CRCA </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Initiative</span><span style="font-family:'Times New Roman'; font-size:11pt">, which crucially would provide the core infrastructure required to support this ambitious programme.  The Programme Plan will include work on basic bacteriology, antibiotic resista</span><span style="font-family:'Times New Roman'; font-size:11pt">nce, epidemiology, chemistry,  </span><span style="font-family:'Times New Roman'; font-size:11pt">drug design and clinical</span><span style="font-family:'Times New Roman'; font-size:11pt"> evaluation. Special arrangements should be made for collaboration with industry, for international cooperation, for specialized training and for the centralized provision of reagents for research use to ensure widespread dissemination and uptake of emerging scientific results and new technologies. CRCA will closely engage with the public, ensuring that the benefits of the research are clearly visible to patients and to the public. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Specific Proposal</span><span style="font-family:'Times New Roman'; font-size:11pt">: </span><span style="font-family:'Times New Roman'; font-size:11pt">A Cross Research Council group (MRC, BBSRC, EPSRC,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">NIHR) initiate a program of  fundamental and developmental research into  antibiotics for the prevention and treatment of bacterial infections.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">ii)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Investment: </span><span style="font-family:'Times New Roman'; font-size:11pt">Industry must be encouraged to re-enter the AMR field. This needs a combination of government and regulatory initiatives. For example, the Limited Population Antimicrobial Drug Pathway (Infectious Disease Society of America) </span><span style="font-family:'Times New Roman'; font-size:11pt">propose</span><span style="font-family:'Times New Roman'; font-size:11pt">s that the development of a new antibiotic should require small clinical trials with patients who are infected with highly resistant bacteria. This would reduce the cost of development. Marketing approval should be given on the basis of successful trial outcome. </span><span style="font-family:'Times New Roman'; font-size:11pt"> The use of the new antibiotic would be restricted </span><span style="font-family:'Times New Roman'; font-size:11pt">to the treatment of patients with highly resistant bacteria. This should reduce the emergence of resistance to the new antibiotic.  Industry would be allowed to charge a high unit </span><span style="font-family:'Times New Roman'; font-size:11pt">price for the antibiotic. This </span><span style="font-family:'Times New Roman'; font-size:11pt">should en</span><span style="font-family:'Times New Roman'; font-size:11pt">courage industry to re-enter</span><span style="font-family:'Times New Roman'; font-size:11pt"> antibiotic discovery and development. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Specific Proposal</span><span style="font-family:'Times New Roman'; font-size:11pt">: NHS England should commission NICE to compile a report on the Limited Population Antimicrobial Drug Pathway and antibiotic unit price relating to encouraging industry into the AMR field. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Public-Private investment: </span><span style="font-family:'Times New Roman'; font-size:11pt">The UK government plays an important leadership role in Europe. It has been sugges</span><span style="font-family:'Times New Roman'; font-size:11pt">ted that </span><span style="font-family:'Times New Roman'; font-size:11pt">the European Commission initiates an antibiotic recovery plan which is based on the concept of the Marshall Plan in 1948. A modern </span><span style="font-family:'Times New Roman'; font-size:11pt">public private partnership </span><span style="font-family:'Times New Roman'; font-size:11pt">precedent for this already exists in USA, and is calle</span><span style="font-family:'Times New Roman'; font-size:11pt">d</span><span style="font-family:'Times New Roman'; font-size:11pt"> the </span><span style="font-family:'Times New Roman'; font-size:11pt">Public Health Emergency Medical Countermeasures Enterprise which contains multiple agencies which focus</span><span style="font-family:'Times New Roman'; font-size:11pt"> on</span><span style="font-family:'Times New Roman'; font-size:11pt"> antibiotic recovery. The Marshall Plan could be funded by loans and grants from the European Commission to the pharmaceutical industry(SMEs and large companies). It is envisaged that for the loans, collateral would be provided by the government, interest rates would be very low, but the money would have to be repaid, whereupon it would be reinvested in antibiotic recovery.</span><span style="font-family:'Times New Roman'; font-size:11pt"> These loans should be long term and should only be repaid once the company is profitable, and even then over a long period. If a large pharmaceutical company buys the biotech, it will only gradually pay back the loan if the project which it bought reaches the market and is successfully marketed. </span><span style="font-family:'Times New Roman'; font-size:11pt"> This principle was successfully used by Germany in 1948, and its share of the Marshall Plan money was loaned</span><span style="font-family:'Times New Roman'; font-size:11pt"> out</span><span style="font-family:'Times New Roman'; font-size:11pt"> numerous tim</span><span style="font-family:'Times New Roman'; font-size:11pt">es over to industry for </span><span style="font-family:'Times New Roman'; font-size:11pt">40 years</span><span style="font-family:'Times New Roman'; font-size:11pt"> or more</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">It is thought that 60% of the fund should be loans and 40% should be grants to universities, SMEs, and major pharmaceutical companies.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Specific Proposal</span><span style="font-family:'Times New Roman'; font-size:11pt">: the UK government should discu</span><span style="font-family:'Times New Roman'; font-size:11pt">ss with the European Commission</span><span style="font-family:'Times New Roman'; font-size:11pt"> an Antibiotic Recovery Plan along the lines of the Marshall Plan or the Public Health Emergency Medical Countermeasures Enterprise.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The largest</span><span style="font-family:'Times New Roman'; font-size:11pt"> public-private</span><span style="font-family:'Times New Roman'; font-size:11pt"> initiative in Europe is t</span><span style="font-family:'Times New Roman'; font-size:11pt">he Innovative Medicines Initiative</span><span style="font-family:'Times New Roman'; font-size:11pt">(IMI). T</span><span style="font-family:'Times New Roman'; font-size:11pt">he pharmaceutical industry association (EFPIA)</span><span style="font-family:'Times New Roman'; font-size:11pt"> and the EU share the funding of this program. We welcome this. At the moment, of the 40 projects, only a small number are aimed at antibiotic discovery and development. This small number should be increased, or a separate program should be set up which is devoted to antibiotic recovery. Because of the substantial involvement of the major pharmaceutical companies, drug development is well served. But, it can only fund existing projects,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and half the money needs to be from industry. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 90pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Specific Proposal</span><span style="font-family:'Times New Roman'; font-size:11pt">: the UK government encourages EU to expand the IMI program focus on antibiotic discovery and development. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">b)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">There is a need for a global over-arching network of scientists who are engaged in antibiotic discovery and development. A possible model for this is the not-for-profit Antibiotic Discovery-UK network of leading academic researchers and universities together with SMEs all of whom have a common goal of revitalising of antibiotic discovery research in the UK. The ex</span><span style="font-family:'Times New Roman'; font-size:11pt">pansion of this network into a g</span><span style="font-family:'Times New Roman'; font-size:11pt">lobal</span><span style="font-family:'Times New Roman'; font-size:11pt"> network would be feasible at a relatively low cost. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Specific Proposal</span><span style="font-family:'Times New Roman'; font-size:11pt">: UK government should encourage the formation of such a global network. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Although</span><span style="font-family:'Times New Roman'; font-size:11pt"> there are precedents in other areas such as malaria, HIV and tuberculosis, there is no global antibiotic discovery organisation. The UK government should encourage organisations such as the </span><span style="font-family:'Times New Roman'; font-size:11pt"> Bill and Melinda Gates Foundation </span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">Open Source Drug Discovery</span><span style="font-family:'Times New Roman'; font-size:11pt">, Drugs for Neglected Diseases Initiative, </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">the</span><span style="font-family:'Times New Roman'; font-size:11pt"> Global Fund </span><span style="font-family:'Times New Roman'; font-size:11pt">and the World Bank to turn their attention to Antibiotic Recovery. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">c)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We welcome and support the Government’s five year plan. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Its strengths are that it most importantly identifies the problems, and proposes seven key areas for future action. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We have described above some areas which we believe could add weight to the five year plan. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Appendix</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xad;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">– </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">List of Antibiotic Discovery-UK members</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">Dr Richard </span><span style="font-family:'Times New Roman'; font-size:11pt">Bax</span><span style="font-family:'Times New Roman'; font-size:11pt"> - </span><span style="font-family:'Times New Roman'; font-size:11pt">Transcrip</span><span style="font-family:'Times New Roman'; font-size:11pt"> Partners</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor </span><span style="font-family:'Times New Roman'; font-size:11pt">Mervyn</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">Bibb</span><span style="font-family:'Times New Roman'; font-size:11pt"> - John Innes Centre, Norwich</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Michael </span><span style="font-family:'Times New Roman'; font-size:11pt">Brockhurst</span><span style="font-family:'Times New Roman'; font-size:11pt"> - University of York</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Kenneth Bruce - King's College, University of London</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Anthony Coates - St George's, University of London</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Anne-</span><span style="font-family:'Times New Roman'; font-size:11pt">Katrin</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Duhme-Klair</span><span style="font-family:'Times New Roman'; font-size:11pt"> - University of York</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Geoff </span><span style="font-family:'Times New Roman'; font-size:11pt">Coxon</span><span style="font-family:'Times New Roman'; font-size:11pt"> - University of Strathclyde</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Lloyd </span><span style="font-family:'Times New Roman'; font-size:11pt">Czaplewski</span><span style="font-family:'Times New Roman'; font-size:11pt"> - </span><span style="font-family:'Times New Roman'; font-size:11pt">Chembioventures</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Christopher Dowson -</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">University of Warwick</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Jeff </span><span style="font-family:'Times New Roman'; font-size:11pt">Errington</span><span style="font-family:'Times New Roman'; font-size:11pt"> - University of Newcastle</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor C. </span><span style="font-family:'Times New Roman'; font-size:11pt">Fishwick</span><span style="font-family:'Times New Roman'; font-size:11pt"> - University of Leeds</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Colin Garner - Garner Consulting</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Stephen Gillespie -</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">St Andrew's University</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr </span><span style="font-family:'Times New Roman'; font-size:11pt">Yanmin</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Hu</span><span style="font-family:'Times New Roman'; font-size:11pt"> - St George's, University of London</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Adrian Lloyd - University of Warwick</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Luigi Martini - King's College (University of London)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Mark </span><span style="font-family:'Times New Roman'; font-size:11pt">Moloney</span><span style="font-family:'Times New Roman'; font-size:11pt"> - University of Oxford</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Alex O'Neill - University of Leeds</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Clive Page - King's College (University of London)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Lloyd Payne - </span><span style="font-family:'Times New Roman'; font-size:11pt">Euprotec</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Laura </span><span style="font-family:'Times New Roman'; font-size:11pt">Piddock</span><span style="font-family:'Times New Roman'; font-size:11pt"> - University of Birmingham</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr David Roper - University of Warwick</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Christopher Schofield - University of Oxford</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Maggie Smith - University of York</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Hannah Sore - University of Cambridge</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr David Spring - University of Cambridge</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Mathew Upton - University of Manchester</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr James Walsh - University of York</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Peter Warn - </span><span style="font-family:'Times New Roman'; font-size:11pt">Euprotec</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div></body></html>